181 related articles for article (PubMed ID: 37142967)
1. Elevated LILRB1 expression predicts poor prognosis and is associated with tumor immune infiltration in patients with glioma.
Zou R; Zhong X; Liang K; Zhi C; Chen D; Xu Z; Zhang J; Liao D; Lai M; Weng Y; Peng H; Pang X; Ji Y; Ke Y; Zhang H; Wang Z; Wang Y
BMC Cancer; 2023 May; 23(1):403. PubMed ID: 37142967
[TBL] [Abstract][Full Text] [Related]
2. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
[TBL] [Abstract][Full Text] [Related]
3. GPR37 expression as a prognostic marker in gliomas: a bioinformatics-based analysis.
Liang K; Guo Z; Zhang S; Chen D; Zou R; Weng Y; Peng C; Xu Z; Zhang J; Liu X; Pang X; Ji Y; Liao D; Lai M; Peng H; Ke Y; Wang Z; Wang Y
Aging (Albany NY); 2023 Oct; 15(19):10146-10167. PubMed ID: 37837549
[TBL] [Abstract][Full Text] [Related]
4. Leukocyte immunoglobulin-like receptor subfamily B member 1 potentially acts as a diagnostic and prognostic target in certain subtypes of adenocarcinoma.
Cheng J; Gao X; Zhang X; Guo H; Chen S; Gou X
Med Hypotheses; 2020 Nov; 144():109863. PubMed ID: 32534335
[TBL] [Abstract][Full Text] [Related]
5. High LYRM4-AS1 predicts poor prognosis in patients with glioma and correlates with immune infiltration.
Wang HY; Xie Y; Du H; Luo B; Li Z
PeerJ; 2023; 11():e16104. PubMed ID: 37810780
[TBL] [Abstract][Full Text] [Related]
6. EFNA1 is a potential key gene that correlates with immune infiltration in low-grade glioma.
Hao YP; Wang WY; Qiao Q; Li G
Medicine (Baltimore); 2021 Jun; 100(22):e26188. PubMed ID: 34087884
[TBL] [Abstract][Full Text] [Related]
7. LILRB1
Xu X; Yin S; Wang Y; Zhu Q; Zheng G; Lu Y; Li T; Zhu C
Int Immunopharmacol; 2023 Jun; 119():110162. PubMed ID: 37075669
[TBL] [Abstract][Full Text] [Related]
8. Selenoprotein GPX1 is a prognostic and chemotherapy-related biomarker for brain lower grade glioma.
Chen X; Fu G; Li L; Zhao Q; Ke Z; Zhang R
J Trace Elem Med Biol; 2022 Dec; 74():127082. PubMed ID: 36155420
[TBL] [Abstract][Full Text] [Related]
9. PLEKHA4 Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Glioma.
Zhang W; Li L; Bian PP; Luo QP; Xiong ZT
Biomed Res Int; 2023; 2023():4504474. PubMed ID: 36714030
[TBL] [Abstract][Full Text] [Related]
10. Poor Prognosis and Therapeutic Responses in LILRB1-Expressing M2 Macrophages-Enriched Gastric Cancer Patients.
Zhang Y; Wang H; Xu X; Liu H; Hao T; Yin S; Zhang C; He Y
Front Oncol; 2021; 11():668707. PubMed ID: 34485116
[TBL] [Abstract][Full Text] [Related]
11. Ferroptosis-related gene signature correlates with the tumor immune features and predicts the prognosis of glioma patients.
Hu Y; Tu Z; Lei K; Huang K; Zhu X
Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34726238
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 Pattern Provides a New Scoring System and Predicts the Prognosis and Immune Therapeutic Response in Glioma.
Jiang F; Lu DF; Zhan Z; Yuan GQ; Liu GJ; Gu JY; Sun XO; Wang Z
Cells; 2022 Dec; 11(24):. PubMed ID: 36552760
[TBL] [Abstract][Full Text] [Related]
13. Identification and validation of transferrin receptor protein 1 for predicting prognosis and immune infiltration in lower grade glioma.
Wu H; He H; Huang J; Wang C; Dong Y; Lin R; Cheng Z; Qiu Q; Hong L
Front Mol Neurosci; 2022; 15():972308. PubMed ID: 36483569
[TBL] [Abstract][Full Text] [Related]
14. The Systematic Landscape of Nectin Family and Nectin-Like Molecules: Functions and Prognostic Value in Low Grade Glioma.
Han Y; Zou C; Zhu C; Liu T; Shen S; Cheng P; Cheng W; Wu A
Front Genet; 2021; 12():718717. PubMed ID: 34925438
[No Abstract] [Full Text] [Related]
15. Tumor mutational burden is associated with poor outcomes in diffuse glioma.
Wang L; Ge J; Lan Y; Shi Y; Luo Y; Tan Y; Liang M; Deng S; Zhang X; Wang W; Tan Y; Xu Y; Luo T
BMC Cancer; 2020 Mar; 20(1):213. PubMed ID: 32164609
[TBL] [Abstract][Full Text] [Related]
16. Interferon gamma-related gene signature based on anti-tumor immunity predicts glioma patient prognosis.
Zhang Z; Shen X; Tan Z; Mei Y; Lu T; Ji Y; Cheng S; Xu Y; Wang Z; Liu X; He W; Chen Z; Chen S; Lv Q
Front Genet; 2022; 13():1053263. PubMed ID: 36712869
[No Abstract] [Full Text] [Related]
17. MCM4 is a novel prognostic biomarker and promotes cancer cell growth in glioma.
Yang S; Yuan Y; Ren W; Wang H; Zhao Z; Zhao H; Zhao Q; Chen X; Jiang X; Zhang L
Front Oncol; 2022; 12():1004324. PubMed ID: 36465369
[TBL] [Abstract][Full Text] [Related]
18. Deciphering the role of QPCTL in glioma progression and cancer immunotherapy.
Liu Y; Lu S; Sun Y; Wang F; Yu S; Chen X; Wu LL; Yang H; Shi Y; Zhao K
Front Immunol; 2023; 14():1166377. PubMed ID: 37063864
[TBL] [Abstract][Full Text] [Related]
19. ECM2, a prognostic biomarker for lower grade glioma, serves as a potential novel target for immunotherapy.
Cheng X; Liu Z; Liang W; Zhu Q; Wang C; Wang H; Zhang J; Li P; Gao Y
Int J Biochem Cell Biol; 2023 May; 158():106409. PubMed ID: 36997057
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the expression and prognosis for leukocyte immunoglobulin-like receptor subfamily B in human liver cancer.
Fan J; Wang L; Chen M; Zhang J; Li J; Song F; Gu A; Yin D; Yi Y
World J Surg Oncol; 2022 Mar; 20(1):92. PubMed ID: 35321724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]